Difference between revisions of "Sirolimus (Rapamune)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m |
||
Line 3: | Line 3: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
+ | *[[Aplastic anemia]] | ||
*[[Autoimmune cytopenias]] | *[[Autoimmune cytopenias]] | ||
*[[Erdheim-Chester disease]] | *[[Erdheim-Chester disease]] | ||
Line 18: | Line 19: | ||
[[Category:mTOR inhibitors]] | [[Category:mTOR inhibitors]] | ||
+ | [[Category:Aplastic anemia medications]] | ||
[[Category:Autoimmune cytopenias medications]] | [[Category:Autoimmune cytopenias medications]] | ||
[[Category:Erdheim-Chester disease medications]] | [[Category:Erdheim-Chester disease medications]] | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
+ | |||
[[Category:FDA approved in 1999]] | [[Category:FDA approved in 1999]] |
Revision as of 20:07, 22 August 2018
Mechanism of action
From the NCI Drug Dictionary: A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production.
Diseases for which it is used
Also known as
- Code names: AY 22989, SILA 9268A, SLM, WY-090217
- Generic names: RAPA, rapamycin
- Brand name: Rapamune